Shanghai, October 28, 2024 / PRNewswire / -- Wuxi Biologics, the world's leading Contract Research, Development, and Manufacturing Organization (CRDMO) service provider (2269.HK) announced the launch of the WuXia RidGS cell line construction platform based on high-yield glutamine synthetase (GS) in Chinese hamster ovary (CHO) expression system. This platform is a non-antibiotic cell line development platform that utilizes Zinc Finger Nuclease (ZFN) technology to knock out the endogenous GS gene in CHO cells.
WuXia RidGS, derived from the WuXia cell line construction platform, inherits strong cell growth, metabolic, and expression levels from WuXia. The average clone expression level of its monoclonal antibody product exceeds 6 g/L. Additionally, WuXia RidGS can ensure the stability of various therapeutic types of cell lines such as monoclonal antibodies, bispecific antibodies, fusion proteins, and recombinant proteins. Moreover, the protein products expressed by this technology platform have good levels of glycosylation modification and high purity. It is worth mentioning that in long-term cell passaging without the use of antibiotics, WuXia RidGS host cells and production cells consistently maintain stable product expression levels and product quality.
Dr. Chris Chen, CEO of WuXi Biologics, stated: "We are pleased to introduce the WuXia RidGS technology platform, providing a more efficient solution for the development of advanced therapeutic protein products. To meet the diverse needs of global customers, WuXi Biologics is committed to building customized self-developed technology platforms. We empower global partners to accelerate the development of innovative drugs, enabling global patients to have access to more accessible high-quality biopharmaceuticals."
About the WuXia cell line construction series platforms
Wuxi Bio has developed a high-yield mammalian cell line construction platform called WuXia, with production levels of up to 11g/L. This technology platform has been recognized by global pharmaceutical regulatory agencies, and has developed over 900 cell lines expressing monoclonal antibodies, bispecific antibodies, fusion proteins, enzymes, and other recombinant proteins for clinical and commercial production. Building on the outstanding features of WuXia, WuXiaADCC Plus and WuXia RidGS actively meet the diversified needs of global customers.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global open-access biologics technology platform offering end-to-end solutions to empower and accelerate biologics discovery, development, and manufacturing. The company's services are designed to help its partners achieve their goals at all stages of the biologics life cycle, from concept to commercial manufacturing. WuXi Biologics' innovative platforms and solution-focused services are designed to help customers bring innovative biologics products to market faster and more efficiently, ultimately benefiting patients worldwide.
Wuxi Bio has over 12,000 employees in China, the USA, Ireland, Germany, and Singapore. Through Wuxi Bio's professional services team, as well as advanced technology and deep insights, the company provides customers with efficient and cost-effective solutions for biopharmaceuticals. As of the end of June 2024, Wuxi Bio has assisted customers in developing and producing a total of 742 comprehensive projects, including 16 commercial production projects (excluding new crown projects and inactive projects).
Wuxi Bio regards environmental, social, and governance (ESG) as an important part of business development and corporate spirit, and is committed to becoming a global leader in ESG in the field of biopharmaceutical CRDMO, leading industry development with greener and more eco-friendly new generation biopharmaceutical technologies and energy, etc. The company has established an ESG committee led by the CEO to fully implement the ESG strategy and uphold sustainable development commitments. For more information, please visit:
